AlloNK® + Anti-CD20 Monoclonal Antibodies in Non-Hodgkin Lymphoma

Our ongoing Phase 1/2 clinical trial ( Identifier: NCT04673617) is assessing the safety and clinical activity of AlloNK® alone and in combination with the anti-CD20 monoclonal antibody, rituximab. The study is enrolling patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) who have progressed beyond two or more prior lines of therapy.

AlloNK® + Acimtamig (AFM13) in CD30-Positive Lymphomas

Artiva and Affimed have entered into a strategic collaboration to jointly develop, manufacture, and commercialize a combination therapy comprised of Artiva’s AlloNK®, and Affimed’s Innate Cell Engager (ICE®) acimtamig (previously known as AFM13) for the treatment of patients with relapsed/refractory CD30-positive lymphomas. The LuminICE-203 study ( Identifier: NCT05883449) is recruiting patients with r/r classical Hodgkin lymphoma and an exploratory arm in r/r PTCL.


AB-201 is our clinical-stage CAR-NK cell therapy candidate targeting HER2-positive solid tumors. We and our partner, GC Cell, are initiating the clinical evaluation of AB-201. The studies will assess AB-201 safety and efficacy in HER2+ breast and gastric/GEJ carcinomas. AB-201 HER2 CAR-NK uses a novel, high affinity HER2-directed antibody converted to Artiva’s proprietary CAR structure and expression of IL-15 for improved cellular persistence. AB-201 cell products maintain high expression of CD16, as well as other activating innate cell tumor engaging receptors, enabling the potential for dual targeting therapeutic approaches via monoclonal antibody combinations. The resulting CAR-NK is manufactured at large scale and cryopreserved in infusion-ready media to enable repeat clinical administrations in the outpatient setting.

AB-205 CD5-Directed CAR-NK

AB-205 has been developed preclinically by Artiva’s strategic partner, GC Cell, for the treatment of CD5+ lymphomas of T-cell origin. AB-205 is currently in IND-enablement studies.

Partnered Programs


Artiva and Affimed have entered into a strategic collaboration to jointly develop, manufacture, and commercialize a combination therapy comprised of AlloNK® and Affimed’s Innate Cell Engager (ICE®) acimtamig (previously known as AFM13). The clinical agreement follows the parties’ previous two-year preclinical collaboration to assess combining elements of the companies’ respective platforms in the generation of targeted, off-the-shelf allogeneic NK cell therapies. As part of the collaboration, the companies evaluated the combination of acimtamig and AlloNK in various preclinical models and generated data that supports development of a co-administered combination therapy.


Artiva and Merck (known as MSD outside the United States and Canada) have entered into an agreement whereby Merck will evaluate the therapeutic potential of combinations of tri-specific NK-cell engager candidates with AlloNK®.

Publications and Presentations

AB-101, an Allogeneic, Non-Genetically Modified, Natural Killer (NK) Cell Therapy, Evaluated as Monotherapy or in Combination with Rituximab in R/R Non-Hodgkin Lymphoma. Presented at: American Society of Clinical Oncology (ASCO) 2023.

AFM13 enhances the anti-tumor activity of AB-101 towards CD30+ tumors, conferring tumor growth control in vivo. Presented at: International Conference of Malignant Lymphoma (ICML) 2023.

Combinatorial Immunotherapy of Tetravalent Bispecific AFM13 and AB-101 NK Cell Product Confers Tumor Growth Control In Vivo. Presented at: Society for Natural Immunity (NK2023).

Evaluation of AB-101, an Allogeneic Cord Blood-derived Natural Killer (NK) Cell Therapy, as an ADCC Enhancer in Hematologic and Solid Tumors. Presented at: Society for Immunotherapy of Cancer (SITC) 2022.

Pre-Clinical Efficacy of AB-101, An Allogeneic Cord-Blood Derived Natural Killer (NK) Cell Therapeutic Candidate, in Combination with Anti-CD38 Antibodies in Models of Multiple Myeloma. Presented at: American Society of Hematology (ASH) 2022.

Development of AB-201, a novel allogeneic anti-HER2-specific CAR-NK cell therapy for the treatment of HER2+ tumors. Presented at: Society for Immunotherapy of Cancer (SITC) 2021.

Expanded Access Policy

Artiva does not currently have an expanded access program for our investigational products. Expanded access, also known as compassionate use, is a potential pathway for a patient with an immediately life-threatening condition or serious disease to gain access to an investigational drug for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.We are focused on enrolling and conducting the clinical trials necessary to bring innovative, safe, and effective products to patients as quickly as possible. Participation in one of our clinical trials is the only way to access Artiva’s investigational products at this time. We encourage patients and healthcare providers interested in our investigational products to learn more about our ongoing studies by visiting Artiva Clinical Studies. For more information, please contact us at

Collaborations and partnerships are key to advancing, accelerating, and accessing life-saving therapies.